Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Shire PLC (NASDAQ:SHPG)

161.71
Delayed Data
As of Jan 20
 -2.40 / -1.46%
Today’s Change
147.60
Today|||52-Week Range
209.22
-5.09%
Year-to-Date
Shire's (SHPG) ADHD Candidate's NDA Accepted by FDA
Jan 20 / Zacks.com - Paid Partner Content
Merrimack (MACK) Goes Uphill: Is a Turnaround Likely?
Jan 17 / Zacks.com - Paid Partner Content
Is Shire plc a Great Stock for Value Investors?
Jan 19 / Zacks.com - Paid Partner Content
Moody markets; Trump hits pharma; Delta flying high?
Jan 12 / CNNMoney.com
Alcobra Stock Down on Poor Late-Stage Data on ADHD Drug
Jan 18 / Zacks.com - Paid Partner Content
Merrimack (MACK) Sells Onivyde Rights to Ipsen for $1B
Jan 09 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close164.11
Today’s open164.43
Day’s range161.24 - 164.55
Volume1,509,927
Average volume (3 months)1,263,339
Market cap$49.5B
Dividend yield0.50%
Data as of 4:00pm ET, 01/20/2017

Growth & Valuation

Earnings growth (last year)-61.89%
Earnings growth (this year)+6.31%
Earnings growth (next 5 years)+13.10%
Revenue growth (last year)+6.79%
P/E ratio82.3
Price/Sales6.33
Price/Book3.29

Competitors

 Today’s
change
Today’s
% change
REGNRegeneron Pharmaceut...-0.85-0.23%
ALXNAlexion Pharmaceutic...-2.38-1.77%
ABTAbbott Laboratories+0.06+0.15%
NVONovo Nordisk-0.10-0.28%
Data as of 4:02pm ET, 01/20/2017

Financials

Next reporting dateFebruary 16, 2017
EPS forecast (this quarter)$3.26
Annual revenue (last year)$6.4B
Annual profit (last year)$1.3B
Net profit margin20.84%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chief Executive Officer &
Executive Director
Flemming Ornskov
Chief Financial Officer &
Executive Director
Jeffrey Poulton
Corporate headquarters
Dublin, Dublin

Forecasts


Search for Jobs